Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alnylam
Biotech
Alnylam, Biogen build noise in Alzheimer's with gene silencing
Alnylam and Biogen published early-phase data on their respective RNAi and antisense approaches to treating the neurodegenerative disease.
Nick Paul Taylor
Oct 26, 2023 8:51am
RNA biotech ADARx hauls in healthy $200M series C
Aug 9, 2023 10:17am
Roche signs onto Alnylam's midstage hypertension med for $310M
Jul 24, 2023 11:00am
BridgeBio heart disease med vindicated with phase 3 victory
Jul 17, 2023 10:12am
Ionis, AstraZeneca crack open phase 3 data of Alnylam rival
Apr 24, 2023 7:00am
66-week data put AstraZeneca on route to rare disease approval
Mar 27, 2023 4:44am